Trials / Terminated
TerminatedNCT03978611
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Relatlimab | Specified dose on specified days |
| DRUG | Ipilimumab | Specified dose on specified days |
Timeline
- Start date
- 2021-12-09
- Primary completion
- 2023-07-26
- Completion
- 2023-07-26
- First posted
- 2019-06-07
- Last updated
- 2024-07-24
Locations
28 sites across 6 countries: United States, Belgium, Canada, Germany, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03978611. Inclusion in this directory is not an endorsement.